Navigation Links
Generic Drug Decision Disastrous to Patient Safety
Date:6/23/2011

WASHINGTON, June 23, 2011 /PRNewswire-USNewswire/ -- Today's U.S. Supreme Court decision in Pliva v. Mensing is a disastrous outcome for patient safety, giving generic drug companies legal immunity when they ignore harmful side-effects of the drugs they manufacture and profit from.  This decision eliminates any incentive for generic manufacturers to ensure their drug is safe and adequately warn consumers of their drugs' potential dangers.

This decision also means that brand-name manufacturers will be held to a different yet safer standard.  The Supreme Court decided in Wyeth v. Levine, brand-name manufacturers are responsible for their warning labels and required to update them at all times.  

"Patients will now be taking generic drugs at their own risk," said American Association for Justice President Gibson Vance. "It is absurd that doctors and patients will have to make medical decisions knowing that only brand-name drug manufacturers – not generics – can be held accountable for their drugs' dangerous side-effects."

Today, 70 percent of all prescription drugs are filled with generic versions, accounting for about 2.6 billion prescriptions every year.  Additionally, the generic drug industry continues to expand – nine of the industry's 10 biggest blockbuster drugs are going off-patent within in the next few years. 

"Congress and the Food and Drug Administration need to quickly address the huge legal disparity between brand-name and generic drugs," said Vance.  "Today's decision sends a dangerous and expensive message to patients: you are safer taking brand-name drugs."

Louis Bograd, Senior Litigation Counsel at the Center for Constitutional Litigation, argued this case on behalf of Mensing, and AAJ also filed an amicus brief.  For more information, visit www.justice.org/courts.  To speak with counsel or parties in Pliva v. Mensing, contact Jennifer.Fuson@justice.org, 202-944-2896.Drugs Expected to Come off Patent in the United States by Year:2011

2012

2014Actos

Plavix

Lexapro

CelebrexCozaar

Seroquel

Singulair

CymbaltaConcerta

Valtrex

Viagra

NexiumEffexor

ZyPrexaRisperdalFlomaxSymbicortImitrexLevaquinLipitorLotrelAs the world's largest trial bar, the American Association for Justice (formerly known as the Association of Trial Lawyers of America) works to make sure people have a fair chance to receive justice through the legal system when they are injured by the negligence or misconduct of others--even when it means taking on the most powerful corporations. Visit http://www.justice.org.


'/>"/>
SOURCE American Association for Justice
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lupin Announces Launch of Generic Levaquin® Tablets
2. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
3. Watson Confirms Court Decision Rejecting Tevas Motion to Prevent Launch of Generic SEASONIQUE®
4. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
5. HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer
6. Breckenridge Announces Approval of Generic Activella® 0.5mg/0.1mg Tablets
7. Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products
8. Mylan Receives Approval for Generic Version of Aricept® Tablets
9. Mylan Receives Approval for Generic Version of Effexor XR® Capsules
10. Reportlinker Adds Generic Pharmaceuticals Industry - Top 200 Generic Pharmaceuticals Industry (Global)
11. Mylan Launches Generic Version of Roxicodone® Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Cardiovascular Surgery Devices - Medical ... Medical Devices sector report, "Cardiovascular Surgery Devices - ... of Cardiovascular Surgery Devices currently in pipeline stage. ... The report provides comprehensive information on the pipeline ... various stages of development. The report reviews major ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
(Date:2/8/2016)... February 8, 2016 --> ... research report "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, ... Management, Cosmetic Surgery, Ophthalmology, Gynecology) - Global Forecasts to ... market over the forecast period of 2015 to 2020. ... 2020, at CAGR of 10.5% from 2015 to 2020. ...
Breaking Medicine Technology:
(Date:2/8/2016)... GA (PRWEB) , ... February 08, 2016 , ... Coast ... cavity-free. February is National Children’s Dental Health Month and family dentist Yvonne Dorrian, DMD, ... p.m. at Coast Dental , located next to Target at 1207 North Peachtree ...
(Date:2/8/2016)... ... 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, chocolates and ... are loved. This year, for more than 5.6 million Americans suffering with Alzheimer’s, those ... enough to remind them of the lives they’ve led and the people they’ve touched. ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... case packer for pouches, bags, and flow wrapped products at WestPack 2015, February ... specialty product manufacturers step up to semi-automatic or fully-automatic case packing with a ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... expansion into Canada to provide its range of unique and advantaged protective ... Quebec City that will provide bilingual customer service and marketing support. A new ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, ... the latest beneficiary of their ongoing community enrichment program. The current campaign fundraises ... schools. Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & ...
Breaking Medicine News(10 mins):